FORMA Therapeutics has expanded its tumor metabolism research alliance with J&J subsidiary Janssen Biotech to an executed license agreement. As part of Janssen’s election to execute a license agreement, FORMA will receive additional undisclosed payments, as well as potential future milestones and royalties on each product. Janssen has also expanded the initial collaboration to include new targets.   “This expanded alliance with Janssen demonstrates FORMA’s ability to execute and deliver qual...